|
Study on Prostate Salvage Using High-dose-rate Brachytherapy
RECRUITINGSponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Actively Recruiting
SponsorInstituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Started2026-03-11
Est. completion2032-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07860528
Summary
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Age over 18 years. * Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive biopsy. * Hormone-sensitive patient. * Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost. Exclusion Criteria: * Metastatic disease. * Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone \<50 ng/dL or \<1.7 nmol/L) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level \>2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST criteria).
Conditions6
Biochemically Recurrent Prostate CarcinomaCancerLocally Recurrent CancerProstate CancerQuality of LifeToxicity Radiation
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorInstituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Started2026-03-11
Est. completion2032-01-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07860528